Cardiovascular disease accounts for approximately 50%
|
|
- Dustin Shanon Smith
- 5 years ago
- Views:
Transcription
1 Prognostic Value of Troponin T and I Among Asymptomatic Patients With End-Stage Renal Disease A Meta-Analysis Nadia A. Khan, MD, MSc, FRCPC; Brenda R. Hemmelgarn, PhD, MD, FRCPC; Marcello Tonelli, MD, MSc, FRCPC; Christopher R. Thompson, MD, CM, FRCPC; Adeera Levin, MD, FRCPC Background The prognostic usefulness of troponin enzymes in end-stage renal disease (ESRD) patients is controversial. To resolve this uncertainty of troponin as a prognostic tool, we conducted a systematic review to quantify the association between elevated troponin I or T and long-term total mortality among ESRD patients not suspected of having acute coronary syndrome. Methods and Results We conducted an unrestricted search from the MEDLINE, EMBASE, and DARE bibliographic databases to December 2004 using the terms troponin.mp. or exp troponin and exp kidney, exp renal, exp kidney disease exp renal replacement therapy. We also manually searched review articles and bibliographies to supplement the search. Studies were included if they were prospective observational studies, used cardiac-specific troponin assays, and evaluated long-term risk of death or cardiac events for asymptomatic ESRD patients. Two authors independently abstracted data on study and patient characteristics. Studies findings were stratified according to troponin T or I levels. We used a random-effects model to pool study results and tested for heterogeneity using 2 testing and used funnel-plot inspection to evaluate the presence of publication bias. Data from 28 studies (3931 patients) published between 1999 and December 2004 were included in this review. Patients received dialysis for a median duration of 4 years, with a mean follow-up of 23 months. From the pooled analysis, elevated troponin T ( 0.1 ng/ml) was significantly associated with increased all-cause mortality (relative risk, 2.64; 95 CI, 2.17 to 3.20). Although the prognostic effect sizes were all consistent with a positive relationship between troponin T and mortality, there was significant heterogeneity in the magnitude of these effect sizes (P 0.015). The funnel plot showed evidence of publication bias. Elevated troponin T was also strongly associated with increased cardiac death. Studies evaluating troponin I included a wide variety of assays and differing cut points, rendering synthesis of the study findings difficult. Conclusions Elevated troponin T ( 0.1 ng/ml) identifies a subgroup of ESRD patients who have poor survival and a high risk of cardiac death despite being asymptomatic. These findings suggest that troponin T is a promising risk stratification tool and may help frame therapeutic decisions. The clinical interpretation of elevated troponin I levels, however, remain unclear, largely because of the lack of standardization of assays. (Circulation. 2005;112: ) Key Words: kidney mortality troponin meta-analysis Cardiovascular disease accounts for approximately 50 of deaths in patients with end-stage renal disease (ESRD). 1,2 Identifying those ESRD patients at high risk for future events is challenging, because they often have silent ischemia or atypical expressions of angina. 3 5 Use of ECG data as diagnostic and prognostic tools is also difficult in this population because of the high prevalence of left ventricular hypertrophy and electrolyte disturbances, which themselves cause ECG abnormalities. Because traditional cardiac risk factors only partially account for the increased cardiovascular disease burden of ESRD patients, better tools for risk stratification are needed. Editorial p 3036 Clinical Perspective p 3096 Over the past decade, data have emerged that suggest that elevated cardiac-specific troponins may predict death among ESRD patients without symptoms of acute coronary syndrome. Although the mechanism of death is unknown, the cardiac-specific troponins T and I are expressed almost exclusively in cardiac muscle among patients with ESRD. 6 9 Because troponin levels are widely used, the assays are relatively inexpensive and unaffected by dialysis 10 ; these levels are a promising risk stratification tool. However, the Received May 4, 2005; accepted July 25, From the Division of Internal Medicine (N.A.K.), Division of Cardiology (C.R.T.), and Division of Nephrology (A.L.), University of British Columbia, and the Division of Nephrology, University of Calgary, Calgary (B.R.H.), and the Division of Nephrology, University of Alberta, Edmonton (M.T.), Alberta, Canada. Correspondence to Nadia A. Khan, MD, 620-B 1081 Burrard St, Vancouver, BC, Canada, V6Z 1Y6 nakhan@shaw.ca 2005 American Heart Association, Inc. Circulation is available at DOI: /CIRCULATIONAHA
2 Khan et al Prognostic Value of Troponin Enzymes in End-Stage Renal Disease 3089 overall prognostic usefulness of the troponins remains unclear. Previous studies, based on retrospective study designs and multiple insensitive assays that cross-react with skeletal troponin, have produced conflicting results. To help resolve this uncertainty of troponin as a prognostic tool, we conducted a systematic review to quantify the association between elevated troponin I or T and long-term total mortality among ESRD patients not suspected of having acute coronary syndrome. To avoid the limitations of previous published reviews, 11,12 we included only prospective study designs, excluded studies using assays that cross-react with skeletal troponin, stratified the analysis by type of troponin assay (I versus T), and evaluated the impact of other prognostic variables besides troponin. To explore the mechanisms that potentially explain this relationship, we examined the additional outcome of cardiovascular death and described the relationship between troponin level and cardiovascular death in various prognostic subgroups. A defined level of cardiac-specific troponin elevation that accurately predicted adverse cardiovascular events would be an invaluable asset in therapeutic decision-making for patients with ESRD. Methods The methods used in this review are in accordance with the Meta-Analysis of Observational Studies in Epidemiology: A Proposal for Reporting. 13 Research Objectives The primary research objective was to determine, by use of systematic review techniques, whether elevated serum troponin I or T predicted higher long-term risk of cardiac death or all-cause mortality among asymptomatic patients with ESRD. A secondary objective was to assess whether study outcomes varied systematically with prognostic variables at the study level (history of cardiovascular disease, diabetes mellitus, or diabetic nephropathy; duration of dialysis; and length of follow-up). Studies Included To minimize differences between studies, we imposed the following methodological restrictions for the inclusion criteria: (1) prospective observational study design; and studies that (2) evaluated prognosis of patients with abnormal levels of either troponin I or T, (3) examined all-cause mortality or cardiac death, or (4) included only asymptomatic patients (ie, no symptoms of acute coronary syndrome). We excluded studies based on qualitative assays or those that used first-generation assays of troponin T, which cross-react with skeletal muscle. Primary authors were contacted if the study did not report data amenable to the creation of 2 2 tables. (A rejection log is available on request.) Finding Relevant Studies To identify relevant studies, MEDLINE (OVID 1966 December 2004), EMBASE (1980 December 2004), the Cochrane review of systematic reviews, and the Database of Abstracts of Reviews of Effects (fourth quarter 2004) were reviewed without language restrictions. The search strategy, developed with an experienced librarian, included the following MeSH terms: troponin.mp or exp troponin and exp kidney, exp renal, exp kidney disease exp renal replacement therapy. We also manually reviewed the bibliographies of all relevant articles to supplement our search. Quality Review and Data Abstraction Two of the reviewers (N.A.K. and B.R.H.) independently reviewed each study for the quality review and abstracted data on study and patient characteristics as well as outcomes. Because there is no standardized quality scoring system for observational studies, the components of the quality review were derived largely from the Egger s quality checklist for prognostic studies. 14 Percentage agreement between the 2 reviewers on the 14 items on the quality review ranged from 77 to 100. Disagreements were resolved by consensus. Statistical Analysis For studies evaluating more than 1 troponin I assay, only the most common manufacturer s assay was reported. For studies evaluating more than 1 cut point, the most common cut point among the individual studies was used for analysis to improve between-study comparisons. To study the quality of the assays, we used the standards set by the European Society of Cardiology and the American College of Cardiology for the definition of myocardial injury. 22 Troponin levels should exceed the 99th percentile value of the reference population to infer myocardial cell injury, the total imprecision at this decision level should not exceed 10, and this level should be at least 5-fold higher than the lower limit of detection. For assessment of data quality and data abstraction, percentage agreement between the 2 reviewers was calculated. Patient, study, and assay quality components and study description were summarized by use of basic descriptive statistics (simple counts and means). Meta-analyses of all outcomes are reported using random-effects models because fixed and random-effects model results were similar and random-effects models tend to produce more conservative estimates. A 2 test for heterogeneity was used to assess betweenstudy heterogeneity. Pooled relative risks were expressed with 95 CIs. We also evaluated studies for publication bias by visually inspecting funnel plots and by the Egger test. From univariate regression analysis, we assessed whether the association between elevated troponins and all-cause mortality varied systematically with certain prognostic variables at the study level (history of cardiovascular disease, diabetes mellitus, or diabetic nephropathy; mean durations of dialysis; and length of follow-up). The regression model relates the prognostic effect of troponin T to the study level covariates, assuming a normal distribution for the residual errors with both a within-study and an additive between-studies component of variance, using an estimate that is based on the restricted maximum likelihood. Values for some factors and the outcome of cardiac death were not available for several studies. For the outcomes of cardiac death and for each meta-regression, only studies whereby the information was available were included in the analysis. The analysis was performed by use of STATA statistical software (Version 7, intercooled, STATA Corp). Results Study Selection From the search strategy, 80 full-text articles were retrieved. Of these, 28 studies met the inclusion criteria and were used for this review. The other 52 studies were excluded largely because they did not evaluate the prognosis of patients with abnormal levels of troponin (35/52), were retrospective analyses (5/52), did not report death or myocardial infarction as an outcome (3/52), evaluated patients with acute coronary syndrome (7/52), included an acute renal failure cohort (1/52), or evaluated the first-generation troponin T assay (1/52). Methodological Quality The 28 prospective observational studies were determined to be of fair quality. Of the primary studies, 100 had described independent, consecutive sampling of their cohort, and 64 had explicitly ascertained that patients did not have any acute
3 3090 Circulation November 15, 2005 TABLE 1. Characteristics of Primary Studies Source No. Age, Mean, y* Male, Mean No. of Years on HD/PD Prior History of CAD or MI, Diabetes Mellitus, Duration of Follow-Up, mo Lost to Follow-Up, Total Mortality, Cardiac Death, Apple F * Beciani M Choy JB Deegan P * defilippi C Dierkes J * Farkouh M Hocher B * Hocher B Iliou MC Ishii J * * Khan IA Lang K Lowbeer C * * Lowbeer C * Mallamaci F Mockel M * Musso P Ooi D Ooi D Peetz D Porter GA Roberts M Roppolo LP Stolear JC Wayand D Wood GNI Yakupoglu U *Median value. HD indicates hemodialysis, PD, peritoneal dialysis. symptoms or signs of acute coronary syndrome. The majority of studies (75) reported at least 1 cardiac risk factor, and 89 reported baseline cardiovascular history. However, only 18 of studies indicated the participants baseline medication use. All studies described the troponin assays used, and most (82) used prespecified, rather than data-dependent, cutoff values used to define normal and abnormal levels. Troponin values were known for all patients. Few studies however, explicitly indicated whether the outcomes or troponin measurements were blinded (35), and only 1 study described any treatments or management of patients during follow-up. The majority (96) of primary studies specified the number of patients lost to follow-up, with most (82) reporting that no patients were lost to follow-up, and only 2 studies had losses that exceeded ,24 Description of Primary Studies The 28 studies were published between 1999 and 2004 and included 3931 patients from 12 countries (Table 1). From all primary studies, 94 of patients were receiving hemodialysis. Of the total population, 58 were males and the median (or mean) ages of the cohorts ranged from 52 to 67 years. The median duration on dialysis was 4 years (interquartile range, 2.8 to 7.6 years). Patients were followed for an average of 23 months (range, 6 to 48 months). Table 1 demonstrates variability in prevalence of diabetes mellitus (or diabetic nephropathy), prior history of cardiovascular disease, length of follow-up of individual studies and mean number of years spent on dialysis across the individual studies. Troponin T and I Assays As discerned from Table 2, the troponin T assays were similar, and studies chose similar cut points (ie, 0.1 ng/ml) to detect abnormal levels. For the troponin T assays, this cut point is close to or greater than the threshold at which there is a 10 total coefficient of variance (ie, the lowest concentration at which 10 imprecision is achieved). This cut point is also 5-fold higher than the lower limit of detection. For the troponin I studies, investigators used multiple different manufacturer assays and varying cut points. Approximately
4 Khan et al Prognostic Value of Troponin Enzymes in End-Stage Renal Disease 3091 TABLE 2. Characteristics of the Assays* Source Assay Assay Name (Generation) Manufacturer Cutpoint for Normal, ng/ml Lower Limit of Detection, ng/ml Total CV 90th Percentile Apple F 19 T Elecsys (3rd) Roche at 0.07 ng/ml 0.01 Choy JB 22 T Elecsys (2nd) Roche 0.1 * at 0.1 ng/ml 0.01 Deegan P 31 T Elecsys (2nd) Roche at 0.1 ng/ml 0.01 defilippi C 26 T Elecsys (3nd) Roche *10 at 0.03 ng/ml 0.01 Dierkes J 27 T Elecsys (2nd) Roche *10 at 0.04 ng/ml 0.01 Hocher B 28 T Elecsys (3nd) Roche *0.01 *10 at 0.03 ng/ml 0.01 Iliou MC 20 T Elecsys (2nd) Roche at 0.1 ng/ml 0.01 Ishii J 32 T Elecsys (2nd) Roche at 0.1 ng/ml 0.01 Lang K 42 T Elecsys (2nd) Roche 0.1 *0.01 *10 at 0.04 ng/ml 0.01 Lowbeer C 43 T Elecsys (2nd) Roche 0.1 * at 0.05 ng/ml 0.01 Mockel M 16 T Elecsys (2nd) Roche 0.1 *0.01 *10 at 0.04 ng/ml 0.01 Musso P 25 T Elecsys (2nd) Roche *10 at 0.04 ng/ml 0.01 Ooi D 23 T Elecsys (2nd, 3rd) Roche 0.1* *0.01 *10 at 0.04 ng/ml 0.01 Peetz D 15 T Elecsys (3nd) Roche *10 at 0.03 ng/ml 0.01 Porter GA 17 T Elecsys (2nd) Roche 0.1 *0.01 *10 at 0.04 ng/ml 0.01 Roppolo LP 45 T Elecsys (2nd) Roche 0.1 *0.01 *10 at 0.04 ng/ml 0.01 Stolear JC 46 T Elecsys (3nd) Roche *10 at 0.03 ng/ml 0.01 Wayand D 47 T Elecsys (2nd) Roche 0.1 * at 0.1 ng/ml 0.01 Wood GNI 47 T Elecsys (2nd) Roche at 0.47 ng/ml 0.01 Apple F 19 I Dimension RxL (2nd) Dade Behring at 0.6 ng/ml 0.07 Beciani M 38 I OPUS plus (2nd) Dade Behring at 0.13 ng/ml 0.1 Choy JB 22 I Dade Behring at 0.5 ng/ml Farkouh M 39 I Stratus (2nd) Dade Behring *10 at 0.10 ng/ml 0.07 Iliou MC 20 I Dimension RxL (2nd) Dade Behring *10 at 0.26 ng/ml 0.07 Ishii J 32 I Access (2nd) Beckman-Coulter at 0.1 ng/ml 0.04 Khan IA 41 I Access (2nd) Sanofi *10 at 0.06 ng/ml 0.04 Lang K 42 I Stratus (2nd) Dade Behring 0.4 *10 at 0.10 ng/ml 0.07 Mockel M 16 I Stratus (2nd) Dade Behring *10 at 0.10 ng/ml 0.07 Musso P 25 I Stratus (2nd) Dade Behring *10 at 0.10 ng/ml 0.07 Peetz D 15 I Stratus (2nd) Dade Behring 0.1 *10 at 0.10 ng/ml 0.07 Porter GA 17 I Stratus (2nd) Dade Behring 0.4 *10 at 0.10 ng/ml 0.07 Roppolo LP 45 I Opus Dade Behring 0.5 *10 at 0.90 ng/ml 0.1 Wayand D 47 I Stratus (2nd) Dade Behring at 0.4 ng/ml 0.07 Yakupoglu U 48 I Immulite (1st) DPC 2.3 *0.2 *10 at 0.6 ng/ml 0.2 Mockel M 16 I Opus (1st) Dade Behring 1.6 *10 at 0.90 ng/ml 0.1 Musso P 25 I Access (2nd) Sanofi 0.03 *10 at 0.06 ng/ml 0.04 Peetz D 15 I ACS: 180 (1st) Bayer 0.15 *10 at 0.37 ng/ml 0.1 Iliou MC 20 I Dimension RxL Dade Behring 0.10 *0.04 *10 at 0.14 ng/ml 0.07 *Refer to data from manufacturers of the troponin assays. 49,50 half of these chosen cut points were less than 5-fold higher than the lower limit of detection, and only 63 were above the threshold associated with a 10 total coefficient of variation. Association of Troponin T With Major Outcomes There were 17 primary studies evaluating the association between troponin T and all-cause mortality. In the forest plot of individual prognostic effect sizes in Figure 1, the lower boundaries of the 95 CIs of almost all trials were greater than 1, suggesting a consistent association between troponin and allcause mortality. The two 95 CIs that crossed 1 were also wide because of the small sample size and low event rates from these studies. 16,25 From the pooled analysis, elevated troponin T was significantly associated with increased all-cause mortality (relative risk RR, 2.64; 95 CI, 2.17 to 3.20). Although the prognostic effect sizes were all consistent with a positive relationship between troponin T and mortality, there was significant heterogeneity (P 0.015) in the magnitude of these effect sizes. The funnel plot (Figure 2) showed evidence of publication
5 3092 Circulation November 15, 2005 Figure 1. Forest plot of primary studies evaluating abnormally elevated troponin T and all-cause mortality. Heterogeneity (df 16), P bias. When we removed the largest study, by Apple and colleagues, 19 heterogeneity among the remaining studies was no longer significant. The study by Apple and colleagues demonstrated a strong association between troponin T and total mortality (RR, 1.72; 95 CI, 1.38 to 2.13). Apple s study was similar in quality and methodology to the remaining studies except that the patient sample had a shorter mean duration of dialysis (1.6 years). There were 8 studies that evaluated the outcome of cardiac death. As depicted in Figure 3, each of these primary studies Figure 2. Begg s funnel plot with 95 CI for troponin T primary studies.
6 Khan et al Prognostic Value of Troponin Enzymes in End-Stage Renal Disease CI, 1.27 to 2.38; P 0.001) (Figure 4). The 2 test for heterogeneity was nonsignificant. However, given the varying assays and cut points used for troponin I assays, mathematically pooled results should be interpreted with caution. We report this pooled result because this is the current best available evidence for clinical practice in those institutions using troponin I assays exclusively, and these results may guide other investigators studying troponin I in ESRD patients. Furthermore, as discerned in Figure 5, the estimates of cardiac death risk were highly variable among the 6 studies evaluating troponin I. Figure 3. Forest plot of primary studies evaluating abnormally elevated troponin T and cardiac death. demonstrated an association between elevated troponin T and cardiac death. Elevated troponin T was strongly associated with a significant increase in long-term cardiac death (RR, 2.55; 95 CI, 1.93 to 3.37; P 0.001). In the sensitivity analysis, effect sizes for troponin T and total mortality were similar when studies that had optimized cut points rather than a priori cut points were removed. 21,26 29 Effect sizes were also similar when studies that evaluated nonhemodialysis patients 30 and had 20 loss to followup 22,23 were removed. Association of Troponin I With Major Outcomes From the 12 studies examining troponin I, elevated troponin I was associated with increased total mortality (RR, 1.74; Other Prognostic Characteristics Seventy-two percent of the primary studies adjusted for other prognostic factors to determine independent associations of troponin with all-cause mortality. Of the 16 troponin T studies that controlled for multiple prognostic factors, 15 demonstrated an independent association between elevated troponin T and all-cause mortality. The majority of these studies controlled for advanced age and presence of cardiovascular disease and diabetes mellitus, all factors strongly associated with mortality. Elevated troponin T was also independently associated with mortality when adjusted for the presence of left ventricular hypertrophy 21,26,31 and left ventricular dysfunction. 26,32,33 Troponin I remained independently associated with mortality in only 2 of 8 troponin I studies that controlled for confounding variables. For troponin T, longer duration of dialysis and longer length of follow-up were associated with an increase in prognostic effect size in both univariate and multivariate meta regression analyses. The proportion of patients with a history of cardiovascular disease or the presence of diabetes mellitus or diabetic nephropathy did not influence the association between troponin T and all-cause mortality. However, Figure 4. Forest plot of primary studies evaluating abnormally elevated troponin I and all-cause mortality.
7 3094 Circulation November 15, 2005 Figure 5. Forest plot of primary studies evaluating abnormally elevated troponin I and cardiac death. when Apple s study 19 was removed, none of the prognostic factors were associated with a significant change in prognostic effect size. Discussion The primary studies found moderate to large increases in risk of cardiac death and all-cause mortality with elevated troponin T among asymptomatic ESRD patients. Our analysis found heterogeneity in the estimates of prognosis and evidence for publication bias, suggesting that the actual pooled estimate for mortality is more modest. However, even considering the outlier study by Apple et al, the association with troponin T and mortality remains significant. The sensitivity analysis and the independent association of troponin T despite adjustment for other prognostic factors support the overall association between elevated troponin T and longterm mortality. A modest association between troponin T and mortality in an asymptomatic population that is otherwise challenging to risk-stratify may have clinical usefulness. The fraction of troponin-positive patients with ESRD is influenced by the assay technology and the discriminator value chosen. Troponin T assays are produced by a single manufacturer, thereby standardizing the assay results. The decision cut point for these troponin T studies was generally 0.1 ng/ml, above both the reference population threshold (0.01 ng/ml) for cardiac injury and the threshold associated with a 10 coefficient of variation, indicating reasonable precision at the 0.1 ng/ml level. This cut point is also consistent with other major prognostic studies of patients with acute coronary syndrome with and without chronic kidney disease. 34,35 For the troponin I studies, investigators used multiple different manufacturer assays and varying cut points. Although the troponin I studies were similar in design, patient population, and outcome, this lack of standardization as well as wide differences in the development of each troponin I assay gave rise to major concerns about our ability to mathematically synthesize these results. Although individual studies generally showed an association between troponin I and long-term all-cause mortality, adjustment for other prognostic factors in these studies did not demonstrate an independent association between troponin I and long-term mortality. These findings suggest that troponin I may not be a viable marker for predicting outcomes. Thus, the controversy surrounding the association between troponin I and all-cause mortality is justified, and the best available evidence does not clarify this association. Understanding the mechanisms that underlie elevation in troponin T levels among ESRD patients is of particular importance to help frame appropriate therapeutic decisions. In non-esrd patients, troponin isoenzymes are an extremely sensitive and specific marker for myocardial cell injury. Previous authors have suggested that the mechanism for a rise in troponin among ESRD patients was a result of noncardiac causes, such as uremic myopathy. However, multiple studies were unable to identify troponin in noncardiac organs, 6 9 and our analysis demonstrates a strong association between elevation in troponin T and cardiac death. Troponin T may detect subclinical myocardial cell injury during the repetitive cardiac stresses provoked by hemodialysis. In addition, other relative ischemic stresses might include undetected heart failure or myocardial remodeling in the setting of left ventricular hypertrophy. Several studies reported an association with elevated troponin T and left ventricular mass index. 36,37 However, as several studies also determined, elevated troponin T remained associated with total mortality despite adjustment for the presence of left ventricular hypertrophy or left ventricular dysfunction. In a prespecified subgroup analysis, defilippi and colleagues 26 reported that multivessel coronary artery disease diagnosed by angiography was more prevalent with progressively greater quartiles of troponin T. Our analysis demonstrates a strong relationship between elevated troponin T and cardiac death; however, additional mechanisms underlying the increased long-term mortality need to be explored. This systematic review serves to clarify the association between troponin T and long-term all-cause mortality in asymptomatic ESRD patients using a large pool of studies and also identified a strong association between troponin T and cardiac death, implying a cardiovascular mechanism of death. The association between elevated troponin T and all-cause mortality is concordant with an earlier review that combined 4 troponin T studies. 12 There are several limitations to this study. The primary studies had several methodological flaws, including lack of reporting of blinding and treatment subsequent to entry into the studies, which may have introduced bias into the results. Although we conducted an unrestricted literature search that included the Database of Abstracts of Reviews of Effects, there was most likely publication bias in the troponin T analyses whereby larger trials had lower estimates of prognosis compared with smaller studies. This bias would tend to
8 Khan et al Prognostic Value of Troponin Enzymes in End-Stage Renal Disease 3095 overinflate the pooled estimate of prognosis. However, almost all studies, including the largest study, by Apple et al, did demonstrate a significant association between troponin T and mortality. Most troponin levels were ascertained from a single measurement, rather than an average of repeated measurements over time. Thus, given the recognized measurement error of biological variables, the true magnitude of association between troponin and mortality may be greater. Although the primary studies did not each statistically adjust for identical covariates or all prognostic factors, most studies controlled for similar and clinically important prognostic variables (eg, age, cardiovascular disease, and diabetes mellitus). Also, an important caveat of this study was that the mortality risks were long term, and association with shortterm mortality or diagnosis of acute myocardial infarction using troponin T is unclear. Conclusions It is often difficult to risk-stratify stable, asymptomatic ESRD patients without the use of costly noninvasive or invasive cardiac studies. Troponin T is a promising prognostic tool, because elevated levels identify a subset of ESRD patients who have poor survival and higher risk of cardiac death. Furthermore, the assays are standardized and readily available. The prognostic usefulness of troponin I, however, remain unclear, largely because of the lack of standardization of assays. Thus, currently, troponin I should not be used to prognosticate risk in this patient population. This analysis corroborates previous postulates that a cardiovascular cause underlies the association between mortality and elevated troponin T. Future studies are needed to elucidate the specific pathogenic mechanisms, and the impact of potential therapeutic interventions. Acknowledgments Dr Khan is supported by postdoctoral fellowship awards from the Canadian Institutes of Health Research (CIHR) and the Michael Smith Foundation for Health Research. Drs Hemmelgarn and Tonelli have received New Investigator awards from the Alberta Heritage Foundation for Medical Research and CIHR. The authors thank the University of British Columbia librarian and the administrative staff at the Center for Health Evaluation and Outcome Sciences for assistance in the literature search. We also gratefully appreciate Drs F. Mallamaci and C. Zoccali for providing raw data for this systematic review and the insightful comments made by Dr Anita Palepu on an earlier draft of the manuscript. References 1. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339: Renal Data System. USRDS 1997 Annual Data Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 1997: D1 D51. (NIH publication No ) 3. Aronow WS, Ahn C, Mercando AD, Epstein S. Prevalence of coronary artery disease, complex ventricular arrhythmias, and silent myocardial ischemia and incidence of new coronary events in older persons with chronic renal insufficiency and with normal renal function. Am J Cardiol. 2000;86: , A9. 4. Nakamura S, Uzu T, Inenaga T, Kimura G. Prediction of coronary artery disease and cardiac events using electrocardiographic changes during hemodialysis. Am J Kidney Dis. 2000;36: Zawada ET Jr, Stinson JB, Done G. New perspectives on coronary artery disease in hemodialysis patients. South Med J. 1982;75: Davis GK, Labugger R, Van Eyk JE, Apple FS. Cardiac troponin T is not detected in Western blots of diseased renal tissue. Clin Chem. 2001;47: Ricchiuti V, Voss EM, Ney A, Odland M, Anderson PAW, Apple FS. Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false positive results by the second generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem. 1998;44: Bodor GS, Peroterfield D, Voss EM, Smith S, Apple FS. Cardiac troponin I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem. 1995;41: Haller C, Zehelein J, Remppis A, Muller Bardorff M, Katus HA. Cardiac troponin T in patients with end stage renal disease: absence of expression in truncal skeletal muscle. Clin Chem. 1998;44: Donnino MW, Karriem-Norwood V, Rivers EP, Gupta A, Nguyen HB, Jacobsen G, McCord J, Tomlanovich MC. Prevalence of elevated troponin I in end-stage renal disease patients receiving hemodialysis. Acad Emerg Med. 2004;11: Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: review and clinical implications. JAm Coll Cardiol. 2002;40: Needham DM, Shufelt KA, Tomlinson G, Scholey JW, Newton GE. Troponin I and T levels in renal failure patients without acute coronary syndrome: a systematic review of the literature. Can J Cardiol. 2004;20: Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283: Egger M, Smith G, Altman D. Systematic Reviews in Health Care. Ed 2. London, UK: Blackwell BMJ Books; Peetz D, Schutt S, Sucke B, Faldum A, Wandel E, Hafner G, Lackner KJ. Prognostic value of troponin T, troponin I, and CK-MB mass in patients with chronic renal failure. Med Klin (Munich). 2003;98: Mockel M, Schindler R, Knorr L, Muller C, Heller G Jr, Stork TV, Frei U. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: a 9-month outcome analysis. Nephrol Dial Transplant. 1999;14: Porter GA, Norton T, Bennett WM. Long term follow up of the utility of troponin T to assess cardiac risk in stable chronic hemodialysis patients. Clin Lab. 2000;46: Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation. 2000;102: Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106: Iliou MC, Fumeron C, Benoit MO, Tuppin P, Calonge VM, Moatti N, Buisson C, Jacquot C. Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. Am J Kidney Dis. 2003;42: Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2002;40: Apple FS, Wu AHB, Jaffe AS. Implementation of the ESC/ACC guidelines for redefinition of myocardial infarction using cardiac troponin assays with special attention to clinical trial issues. Am Heart J. 2002; 144: Choy JB, Armstrong PW, Ulan RA, Campbell PM, Gourishankar S, Prosser CI, Tymchak WJ. Do cardiac troponins provide prognostic insight in hemodialysis patients? Can J Cardiol. 2003;19: Ooi DS, Zimmerman D, Graham J, Wells GA. Cardiac troponin T predicts long-term outcomes in hemodialysis patients. Clin Chem. 2001; 47: Musso P, Cox I, Vidano E, Zambon D, Panteghini M. Cardiac troponin elevations in chronic renal failure: prevalence and clinical significance. Clin Biochem. 1999;32: defilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, Uretsky B, Smiley M, Gold J, Muniz H, Badalamenti J, Herzog C, Henrich W. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003;290:
9 3096 Circulation November 15, Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation. 2000;102: Hocher B, Ziebig R, Krause R, Asmus G, Neumayer HH, Liefeldt L, Stasch JP. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. Circulation. 2004;109: Ooi DS, Veinot JP, Wells GA, House AA. Increased mortality in hemodialyzed patients with elevated serum troponin T: a one-year outcome study. Clin Biochem. 1999;32: Wood GN, Keevil B, Gupta J, Foley R, Bubtana A, McDowell G, Ackrill P. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. Nephrol Dial Transplant. 2003;18: Deegan PB, Lafferty ME, Blumsohn A, Henderson IS, McGregor E. Prognostic value of troponin T in hemodialysis patients is independent of comorbidity. Kidney Int. 2001;60: Ishii J, Nomura M, Okuma T, Minagawa T, Naruse H, Mori Y, Ishikawa T, Kurokawa H, Hirano T, Kondo T, Nagamura Y, Ezaki K, Hishida H. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. Clin Chim Acta. 2001;312: Lowbeer C, Gutierrez A, Gustafsson SA, Norrman R, Hulting J, Seeberger A. Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. Nephrol Dial Transplant. 2002;17: Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, Mahaffey KW, Newby LK, Califf RM, Simoons ML, Topol EJ, Berger P, Lauer MS. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med. 2002;346: Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr, Califf RM, Topol EJ. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med. 1996;335: Lowbeer C, Gustafsson SA, Seeberger A, Bouvier F, Hulting J. Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. Scand J Clin Lab Invest. 2004;64: Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS, Cardiovascular Risk Extended Evaluation in Dialysis Investigators. Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. Kidney Int. 2002;62: Beciani M, Tedesco A, Violante A, Cipriani S, Azzarito M, Sturniolo A, Splendiani G. Cardiac troponin I (2nd generation assay) in chronic haemodialysis patients: prevalence and prognostic value. Nephrol Dial Transplant. 2003;18: Farkouh ME, Robbins MJ, Urooj Zafar M, Shimbo D, Davidson KW, Puttappa R, Winston J, Halperin JL, Epstein EM, Patel M, Talor Z, Chesebro JH. Association between troponin I levels and mortality in stable hemodialysis patients. Am J Med. 2003;114: Hocher B, Ziebig R, Altermann C, Krause R, Asmus G, Richter CM, Slowinski T, Sinha P, Neumayer HH. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol. 2003;14: Khan IA, Wattanasuwan N, Mehta NJ, Tun A, Singh N, Singh HK, Vasavada BC, Sacchi TJ. Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: a two-year outcome analysis. J Am Coll Cardiol. 2001;38: Lang K, Schindler S, Forberger C, Stein G, Figulla HR. Cardiac troponins have no prognostic value for acute and chronic cardiac events in asymptomatic patients with end-stage renal failure. Clin Nephrol. 2001;56: Lowbeer C, Gutierrez A, Gustafsson SA, Norrman R, Hulting J, Seeberger A. Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. Nephrol Dial Transplant. 2002;17: Roberts MA, Fernando D, Macmillan N, Proimos G, Bach LA, Power DA, Ratnaike S, Ierino FL. Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic hemodialysis. Clin Nephrol. 2004;61: Roppolo LP, Fitzgerald R, Dillow J, Ziegler T, Rice M, Maisel A. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran s Hospital: a pilot study. J Am Coll Cardiol. 1999;34: Stolear JC, Georges B, Shita A, Verbeelen D. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. Nephrol Dial Transplant. 1999;14: Wayand D, Baum H, Schatzle G, Scharf J, Neumeier D. Cardiac troponin T and I in end-stage renal failure. Clin Chem. 2000;46: Yakupoglu U, Ozdemir FN, Arat Z, Haberal A, Agca E, Bilgin N. Can troponin-i predict cardiovascular mortality due to myocardial injury in hemodialysis patients? Transplant Proc. 2002;34: Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem. 2003;49: Panteghini M, Pagani F, Yeo KT, Apple FS, Christenson RH, Dati F, Mair J, Ravkilde J, Wu AH, Committee on Standardization of Markers of Cardiac Damage of the IFCC. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem. 2004;50: CLINICAL PERSPECTIVE Whether cardiac-specific troponin enzymes can predict death among patients with end-stage renal disease (ESRD) is unclear. To resolve this uncertainty, we conducted a systematic review to quantify the association between elevated troponin I or T and long-term total mortality among ESRD patients not suspected of having acute coronary syndrome. From 17 studies, we found that elevated troponin T ( 0.1 ng/ml) is significantly associated with increased all-cause mortality (relative risk, 2.64; 95 CI, 2.17 to 3.20). Although the prognostic effect sizes were all consistent with a positive relationship between troponin T and mortality, there was significant heterogeneity in the magnitude of these effect sizes (P 0.015). Elevated troponin T was also strongly associated with increased cardiac death. Studies evaluating troponin I included a wide variety of assays and differing cut points, rendering synthesis of the study findings difficult. Identifying those ESRD patients at high risk for future events is challenging, because they often have silent ischemia or atypical expressions of angina. Elevated troponin T ( 0.1 ng/ml) identifies a subgroup of ESRD patients who have poor survival and a high risk of cardiac death despite being asymptomatic. These findings suggest that troponin T is a promising risk stratification tool and may help frame therapeutic decisions. The clinical interpretation of elevated troponin I levels, however, remains unclear, largely because of the lack of standardization of assays.
Cardiac troponin and C-reactive protein for predicting all-cause and cardiovascular mortality in patients with chronic kidney disease: A meta-analysis
REVIEW Cardiac troponin and C-reactive protein for predicting all-cause and cardiovascular mortality in patients with chronic kidney disease: A meta-analysis Wei-Jie Li, I Xu-Miao Chen, I Xiao-Ying Nie,
More informationEffective Health Care Program
Comparative Effectiveness Review Number 135 Effective Health Care Program Cardiac Troponins Used as Diagnostic and Prognostic Tests in Patients With Kidney Disease Executive Summary Background Cardiac
More informationAnalytical performance of the i-stat cardiac troponin I assay
Clinica Chimica Acta 345 (2004) 123 127 www.elsevier.com/locate/clinchim Analytical performance of the i-stat cardiac troponin I assay Fred S. Apple a, *, MaryAnn M. Murakami a, Robert H. Christenson b,
More informationProtein Markers. Clinical Chemistry 49: (2003) Proteomics and
Clinical Chemistry 49:12 2020 2026 (2003) Proteomics and Protein Markers Prognostic Value of Combination of Cardiac Troponin T and B-Type Natriuretic Peptide after Initiation of Treatment in Patients with
More informationSurvival of Patients on the Kidney Transplant Wait List: Relationship to Cardiac Troponin T
American Journal of Transplantation 28; 8: 2352 2359 Wiley Periodicals Inc. C 28 The Authors Journal compilation C 28 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationModerate Renal Dysfunction is not Associated with Elevated Troponin T in Acute Coronary Syndromes
Moderate Renal Dysfunction is not Associated with Elevated Troponin T in Acute Coronary Syndromes Luis C. L. Correia, Carolina E. Barbosa, Thais Cerqueira, Ana Vasconcelos, Saulo Merelles, Tiago Reis,
More informationCAD in Chronic Kidney Disease. Kuang-Te Wang
CAD in Chronic Kidney Disease Kuang-Te Wang InIntroduction What I am going to talk about: CKD and its clinical impact on CAD Diagnosis of CAD in CKD PCI / Revasc Outcomes in CKD CKD PCI CAD Ohtake T,
More informationMeasurement of circulating troponin Ic enhances the prognostic value of C-reactive protein in haemodialysis patients
NDT Advance Access published July 13, 2004 Nephrol Dial Transplant (2004) 1 of 6 DOI: 10.1093/ndt/gfh365 Original Article Measurement of circulating troponin Ic enhances the prognostic value of C-reactive
More informationCardiac Troponins and Renal Function in Nondialysis Patients with Chronic Kidney Disease
Papers in Press. First published September 15, 2005 as doi:10.1373/clinchem.2005.055665 Clinical Chemistry 51:11 000 000 (2005) Proteomics and Protein Markers Cardiac Troponins and Renal Function in Nondialysis
More informationPharmacologyonline 2: (2010) Newsletter Kakadiya and Shah
ROLE OF CREATINE KINASE MB AND LACTATE DEHYDROGENASE IN CARDIAC FUNCTION A REVIEW Jagdish Kakadiya*, Nehal Shah Department of Pharmacology, Dharmaj Degree Pharmacy College, Petlad- Khambhat Road, Dharmaj,
More informationPLASMA LEVELS OF BRAIN NATRIURETIC PEPTIDES AND CARDIAC TROPONIN IN HEMODIALYSIS PATIENTS
& PLASMA LEVELS OF BRAIN NATRIURETIC PEPTIDES AND CARDIAC TROPONIN IN HEMODIALYSIS PATIENTS Halima Resić*, Selma Ajanović, Nihad Kukavica, Fahrudin Mašnić, Aida Ćorić Haemodialysis Clinic, University of
More informationPrognostic Value of C-Reactive Protein and Troponin T Level in Patients With Unstable Angina Pectoris C T KASANUKI, MD, FJCC
C T Prognostic Value of C-Reactive Protein and Troponin T Level in Patients With Unstable Angina Pectoris Hiroyuki Yukio Hiroshi TANAKA, MD TSURUMI, MD KASANUKI, MD, FJCC Abstract Objectives. The prognosis
More informationThe Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients
The Journal of International Medical Research 2003; 31: 76 83 The Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients S VATANSEVER 1, V AKKAYA
More informationCardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray
Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe the acute
More informationLipoproteins and Cardiovascular Risk Factors. Clinical Chemistry 53: (2007)
Clinical Chemistry 53:5 882 889 (2007) Lipoproteins and Cardiovascular Risk Factors Prognostic Value of Cardiac Troponin T Is Independent of Inflammation, Residual Renal Function, and Cardiac Hypertrophy
More informationCardiac Troponins in Renal Insufficiency Review and Clinical Implications
Journal of the American College of Cardiology Vol. 40, No. 12, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02608-6
More information13. RECOMMENDATIONS ON USE OF BIOCHEMICAL MARKERS IN ACUTE CORONARY SYNDROME: IFCC PROPOSALS
13. RECOMMENDATIONS ON USE OF BIOCHEMICAL MARKERS IN ACUTE CORONARY SYNDROME: IFCC PROPOSALS Prof. Mauro Panteghini, MD, Ph.D. Chairman of the IFCC Committee on Standardization of Markers of Cardiac Damage
More informationP1: OTE/SPH P2: OTE BLUK084-Adams April 13, :13 PART 1. Cardiac troponins
PART 1 Cardiac troponins 1 2 CHAPTER 1 Basics of cardiac troponin: practical aspects of assays, potential analytical confounders, and clinical interpretation Fred S. Apple Case 1 Following an episode of
More informationOverall Changes of the Universal Myocardial Infarction Definition
Overall Changes of the Universal Myocardial Infarction Definition Professor Kristian Thygesen, FESC, FACC, FAHA Aarhus University Hospital, Aarhus, DK Co-Chairman of The Global MI Task Force Declaration
More informationPapers in Press. Published March 23, 2007 as doi: /clinchem
Papers in Press. Published March 23, 2007 as doi:10.1373/clinchem.2006.084715 The latest version is at http://www.clinchem.org/cgi/doi/10.1373/clinchem.2006.084715 Clinical Chemistry 53:4 547 551 (2007)
More informationTroponin when is an assay high sensitive?
Troponin when is an assay high sensitive? Professor P. O. Collinson MA MB BChir FRCPath FRCP edin MD FACB EurClin Chem Consultant Chemical Pathologist and Professor of Cardiovascular Biomarkers, Departments
More informationCardiac-specific troponin I (ctni) has been under intensive
Original Articles Association of Mild Transient Elevation of Troponin I Levels With Increased Mortality and Major Cardiovascular Events in the General Patient Population G. Steinar Gudmundsson, MD; Stephen
More informationPeter A. Kavsak, 1* Andrew R. MacRae, 2 Glenn E. Palomaki, 3 Alice M. Newman, 4 Dennis T. Ko, 4 Viliam Lustig, 2 Jack V. Tu, 4 and Allan S.
Clinical Chemistry 52:11 2028 2035 (2006) Evidence-Based Laboratory Medicine and Test Utilization Health Outcomes Categorized by Current and Previous Definitions of Acute Myocardial Infarction in an Unselected
More informationTroponin T in patients with low grade or atypical angina
European Heart Journal (1998) 19, 1802 1807 Article No. hj981233 Troponin T in patients with low grade or atypical angina Identification of a high risk group for short- and long-term cardiovascular events
More informationAssessment of High-Sensitive Cardiac Troponin I in Coronary Artery Disease Patients Undergoing Regular Hemodialysis
The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (4), Page 6571-6576 Assessment of High-Sensitive Cardiac Troponin I in Coronary Artery Disease Patients Undergoing Regular Hemodialysis
More informationHigh Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.
High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer
More informationSupplementary Online Content
Supplementary Online Content Wu HY, Peng YS, Chiang CK, et al. Diagnostic performance of random urine samples using albumin concentration vs ratio of albumin to creatinine for microalbuminuria screening
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationPerioperative myocardial cell injury: the role of troponins
British Journal of Anaesthesia 1997; 78: 386 390 Perioperative myocardial cell injury: the role of troponins H. METZLER, M. GRIES, P. REHAK, TH. LANG, S. FRUHWALD AND W. TOLLER Summary Early recognition
More informationSupplementary Online Content
Supplementary Online Content Rubini Giménez M, Twerenbold R, Boeddinghaus J, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction.
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationStress ECG is still Viable in Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh
Stress ECG is still Viable in 2016 Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh Stress ECG Do we still need stress ECG with all the advances we have in the CV field?
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationEarly risk stratification is essential in the management of
Cystatin C A Novel Predictor of Outcome in Suspected or Confirmed Non ST-Elevation Acute Coronary Syndrome Tomas Jernberg, MD, PhD; Bertil Lindahl, MD, PhD; Stefan James, MD, PhD; Anders Larsson, MD, PhD;
More informationRuling out acute myocardial infarction early with two serial creatine kinase-mb mass determinations
European Heart Journal (1999) 20, 967 972 Article No. euhj.1998.1449, available online at http://www.idealibrary.com on Ruling out acute myocardial infarction early with two serial creatine kinase-mb mass
More informationSafe discharge from the cardiac emergency room with a rapid rule-out myocardial infarction protocol using serial CK-MB mass
Heart 2001;85:143 148 143 Department of Cardiology, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands R Bholasingh R J de Winter J C Fischer R W Koster RJGPeters G T Sanders Correspondence
More informationUse of Biomarkers for Detection of Acute Myocardial Infarction
Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationAssociation between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis
Association between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis Y. Liu, H.L. Liu, W. Han, S.J. Yu and J. Zhang Department of Cardiology, The General Hospital of the
More informationJournal of the American College of Cardiology Vol. 40, No. 6, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 40, No. 6, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02119-8
More informationDefining rise and fall of cardiac troponin values
Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationArticle in press - uncorrected proof
Clin Chem Lab Med 2006;44(6):768 773 2006 by Walter de Gruyter Berlin New York. DOI 10.1515/CCLM.2006.125 2006/60 Integration between the Tele-Cardiology Unit and the central laboratory: methodological
More informationCardiac Troponin I Levels and Clinical Outcomes in Patients With Acute Coronary Syndromes The Potential Role of Early Percutaneous Revascularization
Journal of the American College of Cardiology Vol. 34, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00434-9 Cardiac
More informationJMSCR Vol 05 Issue 01 Page January 2017
JMSCR Vol Issue Page 93-943 January 27 www.jmscr.igmpublication.org Impact Factor.84 Index Copernicus Value: 83.27 ISSN (e)-2347-76x ISSN (p) 24-4 DOI: https://dx.doi.org/.83/jmscr/vi.3 Elevation of Troponin-I
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationDiagnostic methods 2: receiver operating characteristic (ROC) curves
abc of epidemiology http://www.kidney-international.org & 29 International Society of Nephrology Diagnostic methods 2: receiver operating characteristic (ROC) curves Giovanni Tripepi 1, Kitty J. Jager
More informationPOOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS
POOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS CHARLES A. HERZOG, M.D., JENNIE Z. MA, PH.D., AND ALLAN J. COLLINS, M.D. ABSTRACT Background Cardiovascular
More informationEDUCATIONAL COMMENTARY UNDERSTANDING THE BENEFITS AND CHALLENGES OF HIGH- SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS
SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationThe patient who describes chest pain to the primary care
ORIGINAL ARTICLE A review of troponins in ischemic heart disease and other conditions Nedaa Skeik MD 1,2,3, Deevia Chandrakant Patel MD 2,4 N Skeik, D Chandrakant Patel. A review of troponins in ischemic
More informationMario Plebani University-Hospital of Padova, Italy
Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO
More informationTroponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy Ziad Hijazi, MD Uppsala Clinical Research Center (UCR) Uppsala University, Sweden Co-authors:
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationTroponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg
Biomarkers for Optimal Management of Heart Failure Troponin Assessment Does it Carry Clinical Message? Stefan Blankenberg University Heart Center Hamburg Congress of the European Society of Cardiology
More informationCardiac troponins and renal disease
Blackwell Science, LtdOxford, UKNEPNephrology1320-53582004 Asian Pacific Society of NephrologyApril 2004928388Review ArticleCardiac troponins and renal diseasejr de Zoysa NEPHROLOGY 2004; 9, 83 88 Review
More informationTopic. Updates on Definition of Myocardial Infarction
Topic Updates on Definition of Myocardial Infarction In the past, general consensus for MI? Definition of MI by WHO - Combination of 2 of 3 characteristics - 1. Typical Symptoms 2. Enzyme Rise 3. Typical
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationAssociation of Cardiac Troponin, CK-MB, and Postoperative Myocardial Ischemia With Long-Term Survival After Major Vascular Surgery
Journal of the American College of Cardiology Vol. 42, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)01069-6
More informationJournal of the American College of Cardiology Vol. 41, No. 3, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 3, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02824-3
More informationAbstract. Introduction. Volume 54 Number 4 Oct. - Dec., Philippine Journal of Internal Medicine. Original Paper
Philippine Journal of Internal Medicine Original Paper A Comparison Between Dialysis Versus Conservative Management as Modes of Treatment in the Management of Elderly Patients with End Stage Renal Disease:
More informationClinical research in AKI Timing of initiation of dialysis in AKI
Clinical research in AKI Timing of initiation of dialysis in AKI Josée Bouchard, MD Krescent Workshop December 10 th, 2011 1 Acute kidney injury in ICU 15 25% of critically ill patients experience AKI
More informationResults. NeuRA Worldwide incidence April 2016
Introduction The incidence of schizophrenia refers to how many new cases there are per population in a specified time period. It is different from prevalence, which refers to how many existing cases there
More informationHigh-Sensitivity Cardiac Troponin in Suspected ACS
15 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes STATE-OF-THE-ART High-Sensitivity Cardiac Troponin in Suspected ACS David A. Morrow, MD, MPH Director, Levine Cardiac Intensive Care
More informationChapter 9: Cardiovascular Disease in Patients With ESRD
Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in adult ESRD patients, with atherosclerotic heart disease and congestive heart failure being the most common conditions
More informationResults. NeuRA Hypnosis June 2016
Introduction may be experienced as an altered state of consciousness or as a state of relaxation. There is no agreed framework for administering hypnosis, but the procedure often involves induction (such
More informationTraumatic brain injury
Introduction It is well established that traumatic brain injury increases the risk for a wide range of neuropsychiatric disturbances, however there is little consensus on whether it is a risk factor for
More informationFrequency and Clinical Implications of Discordant Creatine Kinase-MB and Troponin Measurements in Acute Coronary Syndromes
Journal of the American College of Cardiology Vol. 47, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.08.062
More informationAlectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis
Showa Univ J Med Sci 30 2, 309 315, June 2018 Original Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis Ryo MANABE 1, Koichi ANDO
More informationLive WebEx meeting agenda
10:00am 10:30am Using OpenMeta[Analyst] to extract quantitative data from published literature Live WebEx meeting agenda August 25, 10:00am-12:00pm ET 10:30am 11:20am Lecture (this will be recorded) 11:20am
More informationComparison of M yoglobin, Creatine Kinase-MB, and Cardiac Troponin I for Diagnosis of Acute Myocardial Infarction*
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 26, No. 4 Copyright 1996, Institute for Clinical Science, Inc. Comparison of M yoglobin, Creatine Kinase-MB, and Cardiac Troponin I for Diagnosis of Acute
More informationDeclaration of conflict of interest. None to declare
Declaration of conflict of interest None to declare Risk management of coronary artery disease Arrhythmias and diabetes Hercules Mavrakis Cardiology Department Heraklion University Hospital Crete, Greece
More information03/07/ Background. + High Risk Features Are Prevalent in Dialysis Patients
+ When Does Cardiovascular Disease Preclude Consideration of Renal Transplantation? Kul Aggarwal, MD, MRCP (UK), FACC Professor of Clinical Medicine Division of Cardiology University of Missouri & Chief,
More informationThe most common cause of death among hemodialysis
Diagnosis of Acute Myocardial Infarction in Hemodialysis Patients With High-Sensitivity Cardiac Troponin T Assay Hua-Lan Huang, MM; Shuai Zhu, MM; Wei-Qing Wang, MM; Xin Nie, MM; Ying-Ying Shi, MD; Yong
More informationPerioperative Myocardial Infarction in Noncardiac Surgery: Focusing on Intraoperative and Postoperative Risk Factors
Perioperative Myocardial Infarction in Noncardiac Surgery: Focusing on Intraoperative and Postoperative Risk Factors Cardiac Unit, Department of Medicine, Prapokklao Hospital, Chantaburi Abstract Perioperative
More informationSetting The setting was the Walter Reed Army Medical Center. The economic study was carried out in the USA.
Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project
More informationACCESS hstni SCIENTIFIC LITERATURE
ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval
More informationNew diagnostic markers for acute coronary syndromes
New diagnostic markers for acute coronary syndromes - Nye diagnostiske markørerer for akutt iskemisk hjertesykdom Bertil Lindahl, Professor Cardiology, Uppsala University and Uppsala Clinical Research
More informationThe Meta on Meta-Analysis. Presented by Endia J. Lindo, Ph.D. University of North Texas
The Meta on Meta-Analysis Presented by Endia J. Lindo, Ph.D. University of North Texas Meta-Analysis What is it? Why use it? How to do it? Challenges and benefits? Current trends? What is meta-analysis?
More informationLow concentrations of high-sensitivity troponin T at presentation to the
Title Page Low concentrations of high-sensitivity troponin T at presentation to the Emergency Department. Running head: Early rule-out using high-sensitivity troponin T Article Type: Letter to the Editor
More informationOnline Supplementary Material
Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Search terms*
Supplementary Figure S1. Search terms* *mh = exploded MeSH: Medical subject heading (Medline medical index term); tw = text word; pt = publication type; the asterisk (*) stands for any character(s) #1:
More informationSpeaker: Richard Heitsman, MICT, C-POC-AACC. Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America.
Speaker: Richard Heitsman, MICT, C-POC-AACC Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America. Upon completion the participant will be able to o Review current and evolving
More informationA New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get from the Laboratory
e-issn 1643-3750 DOI: 10.12659/MSM.892033 Received: 2014.07.18 Accepted: 2014.08.14 Published: 2015.01.28 A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get
More informationTable. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer.
Table. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer. Commercially available assays - Company/ platform(s)/ assay LoB a LoD b 99 th
More informationImprovement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of
More informationAmbulatory arterial stiffness index as a predictor of cardiovascular events.
Ambulatory arterial stiffness index as a predictor of cardiovascular events. A meta-analysis of longitudinal studies. Konstantinos Aznaouridis, Charalambos Vlachopoulos, Christodoulos Stefanadis. 1 st
More informationCritical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto
Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death Debra Moy Faculty of Pharmacy University of Toronto Goal To provide practitioners with a systematic approach to evaluating a meta analysis
More informationResults. NeuRA Treatments for internalised stigma December 2017
Introduction Internalised stigma occurs within an individual, such that a person s attitude may reinforce a negative self-perception of mental disorders, resulting in reduced sense of selfworth, anticipation
More information1. Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: data from the Heart and Soul study Hsieh, B.P., et al. Am
More informationSystematic Reviews and Meta- Analysis in Kidney Transplantation
Systematic Reviews and Meta- Analysis in Kidney Transplantation Greg Knoll MD MSc Associate Professor of Medicine Medical Director, Kidney Transplantation University of Ottawa and The Ottawa Hospital KRESCENT
More informationTroponin = 35. Objectives. Low Risk Chest Pain. Does this patient have ACS? Does this patient have ACS? Objectives
Objectives Low Risk Chest Pain Jeffrey Tabas, MD Professor of Emergency Medicine Office of CME UCSF School of Medicine Improve speed and accuracy in assessing patients with possible ACS! Avoid pitfalls
More informationOvercoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD
Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Disclosures Research contracts: AstraZeneca, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company,
More informationCorrelation of Antemortem Serum Creatine Kinase, Creatine Kinase-MB, Troponin I, and Troponin T with Cardiac Pathology
Clinical Chemistry 46:3 338 344 (2000) Enzymes and Protein Markers Correlation of Antemortem Serum Creatine Kinase, Creatine Kinase-MB, Troponin I, and Troponin T with Cardiac Pathology Daylily S. Ooi,
More informationRapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay
Original Article Annals of Clinical Biochemistry 2015, Vol. 52(5) 543 549! The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563215576976 acb.sagepub.com
More informationLow Risk Chest Pain. Objectives. Disclosure. Case 1. Jeffrey Tabas, MD Professor of Emergency Medicine Office of CME UCSF School of Medicine
Disclosure Low Risk Chest Pain No Financial Relationships to Disclose No significant investments or savings Unlimited Expenses Jeffrey Tabas, MD Professor of Emergency Medicine Office of CME UCSF School
More informationType of intervention Diagnosis. Economic study type Cost-effectiveness analysis.
The utility and potential cost-effectiveness of stress myocardial perfusion thallium SPECT imaging in hospitalized patients with chest pain and normal or non-diagnostic electrocardiogram Ben-Gal T, Zafrir
More informationMeta-Analysis. Zifei Liu. Biological and Agricultural Engineering
Meta-Analysis Zifei Liu What is a meta-analysis; why perform a metaanalysis? How a meta-analysis work some basic concepts and principles Steps of Meta-analysis Cautions on meta-analysis 2 What is Meta-analysis
More informationPrevalence of cardiovascular damage in early renal disease
Nephrol Dial Transplant 2001) 16 wsuppl 2x: 7±11 Prevalence of cardiovascular damage in early renal disease Adeera Levin University of British Columbia, Renal Insuf ciency Clinic, Vancouver, Canada Abstract
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationHigh-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More informationGUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT
GUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT sponsored by TROPONIN OVERVIEW TROPONIN DETECTION IN NORMAL AND DISEASE STATES1 The detection of
More information